Abstract
In a small group of hemodialysis patients with confirmed SARS-CoV-2 infection, we reported that the presence of anti–SARS-CoV-2 IgG overlaps by several weeks with detectable viral RNA in the upper airways.1De Vriese A.S. Reynders M. IgG antibody response to SARS-CoV-2 infection and viral RNA persistence in patients on maintenance hemodialysis.Am J Kidney Dis. 2020; 76: 440-441Abstract Full Text Full Text PDF PubMed Scopus (26) Google Scholar The core message of our communication is that this antibody response, although proof of recent exposure to SARS-CoV-2, should not be interpreted as prima facie evidence of immunity to the virus. Viral load was highest during the first week of illness, suggesting that patients are most infectious during this period. It remains unclear whether the lower viral loads during the following weeks associate with a clinically relevant transmissibility of SARS-CoV-2 requiring further quarantining. As also advocated by Dudreuilh et al2Dudreuilh C. Kumar N. Moxham V. Hemsley C. Goldenberg S. Moutzouris D.A. De-isolation of COVID-19-positive hemodialysis patients in the outpatient setting: a single-center experience.Kidney Int. 2020; 98: 236-237Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar and pending further evidence, we submit that the prudent approach is to await negative reverse transcriptase–polymerase chain reaction test results. We measured anti–SARS-CoV-2 IgG with an N protein–based enzyme-linked immunosorbent assay (NovaLisa; NovaTec). Dudreuilh et al suggest that the combination with an S protein–based assay may provide additional information.3Dudreuilh C. Moutzouris D.-A. Is SARS-CoV-2 serology relevant for hemodialysis patients with COVID-19? Am J Kidney Dis.Am J Kidney Dis. 2020; 76: 598Abstract Full Text Full Text PDF Scopus (4) Google Scholar We have repeated our analyses with a combined S1 (spike protein subunit 1)– and N-protein–based assay (Vircell).4Kohmer N. Westhaus S. Rühl C. Ciesek S. Rabenau H.F. Clinical performance of different SARS-CoV-2 IgG antibody tests. J Med Virol.https://doi.org/10.1002/jmv.26145Google Scholar Although there was a slight variation in the individual immune responses, as clearly described in the literature, the overall conclusion (100% seroconversion within the first few weeks of symptom onset) remains unaltered. Dudreuilh et al rightly point out that the clinical relevance of the anti–SARS-CoV-2 antibody response is currently unclear. Further studies in larger populations of both survivors and nonsurvivors with prolonged sequential sampling starting from the onset of infection are required to determine the longevity of the antibody response and potential correlation with severity of disease in hemodialysis patients. However, more importantly, research should be directed at identifying biomarkers of immunity that can be used to ascertain natural or vaccine-induced resistance to the virus in both the general and hemodialysis populations. The authors declare that they have no relevant financial interests. Received June 20, 2020. Accepted June 24, 2020, after editorial review by an Associate Editor and a Deputy Editor. Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?American Journal of Kidney DiseasesVol. 76Issue 4PreviewAlthough dialysis patients are known to have impaired antibody responses to pathogens and fluctuation of antibody levels,1 the response to coronavirus disease 2019 (COVID-19) in this population remains to be determined. De Vriese and Reynders2 present the first evaluation of potential antibody responses in a dialysis population. We agree that 2 sequential negative COVID-19 swabs before de-isolating dialysis patients is a reasonable approach, as we recently demonstrated.3 De Vriese and Reynders studied the presence of immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein in 7 patients and concluded that patients develop an antibody response within 15 days. Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.